Objective
Cerebral edema(CE) is a key poor prognosticator in TBI. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies. Sulfonylurea Receptor-1(Sur1) is upregulated only after brain injury, causing edema in animal studies. We hypothesized that Sur1 is measurable in human CSF after severe TBI (sTBI) and is an informative biomarker of edema and outcome.
Methods
119 CSF samples were collected from 28 sTBI patients. Samples were retrieved at 12, 24, 48, 72h, and before EVD removal. 15 control samples were obtained from patients with normal pressure hydrocephalus. Sur1 was quantified by ELISA. Outcomes included CT edema, ICP measurements, therapies targeting edema and 3-month Glasgow Outcome Scale score.
Results
Sur1 was present in all sTBI patients (mean=3.54±3.39ng/ml, peak=7.13±6.09ng/ml) but undetectable in all controls (p<0.001). Mean and peak Sur1 was higher in patients with CT edema (4.96±1.13 ng/ml vs. 2.10±0.34 ng/ml, p=0.023). There was a temporal delay between peak Sur1 and peak ICP in 91.7% of patients with intracranial hypertension. There was no association between mean/peak Sur1 and mean/peak ICP, proportion of ICP > 20 mmHg, use of edema-directed therapies, decompressive craniotomy or 3 month Glasgow Outcome Score. However, decreasing Sur1 trajectories between 48–72h were significantly associated with improved CE and clinical outcome. Area under the multivariate model ROC curve was 0.881.
Interpretation
This is the first report quantifying human CSF Sur1. Sur1 was detected in sTBI, absent in controls, correlated with CT-edema and preceded peak ICP. Sur1 trajectories between 48–72h were associated with outcome. Since a therapy inhibiting Sur1 is available, assessing CSF Sur1 in larger studies is warranted to evaluate our exploratory findings regarding its diagnostic, and monitoring utility, as well as its potential to guide targeted therapies in TBI and other diseases involving CE.